Literature DB >> 22528228

Implication of expression of Nanog in prostate cancer cells and their stem cells.

Chen Gong1, Hui Liao2, Fengjin Guo1, Liang Qin1, Jun Qi1.   

Abstract

Recent studies suggested that the prostate cancer may arise from prostate cancer stem cells that share some same characteristics with normal stem cells. The purpose of this study was to detect the differences of Nanog expression between PC3 prostate cancer cell line and its tumor stem cells, and the relationship was preliminarily examined between Nanog and prostate cancer and its tumor stem cells. By using magnetic active cell sorting (MACS), we isolated a population of CD44(+)/CD133(+) prostate cancer cells that display stem cell characteristics from PC3 cell line. Immunohistochemistry revealed positive expressions of CD44, CD133 and α(2)β(1)-integin in the isolated cells. CCK-8 analysis showed that isolated cells had a strong proliferative ability. The formation of the cell spheres in serum-free medium and holoclones in serum-supplied medium showed that the cells were capable of self-renewing, indicating that the isolated cells were a population of cancer stem-like cells derived from PC3 cell line. Western blotting exhibited that the isolated cells had higher experession of Nanog, an embryonic stem marker, as compared with PC3 cells. Our study showed that Nanog might be helpful in sustaining the self-renewal and the undifferentiation of prostate cancer stem cells, and may serve as a marker for prostate cancer stem cells for isolation and identification.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22528228     DOI: 10.1007/s11596-012-0043-5

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  27 in total

1.  Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells.

Authors:  Ian Chambers; Douglas Colby; Morag Robertson; Jennifer Nichols; Sonia Lee; Susan Tweedie; Austin Smith
Journal:  Cell       Date:  2003-05-30       Impact factor: 41.582

2.  Prospective identification of tumorigenic prostate cancer stem cells.

Authors:  Anne T Collins; Paul A Berry; Catherine Hyde; Michael J Stower; Norman J Maitland
Journal:  Cancer Res       Date:  2005-12-01       Impact factor: 12.701

3.  Identification of bronchioalveolar stem cells in normal lung and lung cancer.

Authors:  Carla F Bender Kim; Erica L Jackson; Amber E Woolfenden; Sharon Lawrence; Imran Babar; Sinae Vogel; Denise Crowley; Roderick T Bronson; Tyler Jacks
Journal:  Cell       Date:  2005-06-17       Impact factor: 41.582

4.  The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells.

Authors:  Donald J Vander Griend; Wouter L Karthaus; Susan Dalrymple; Alan Meeker; Angelo M DeMarzo; John T Isaacs
Journal:  Cancer Res       Date:  2008-12-01       Impact factor: 12.701

5.  Stem-like cells in bone sarcomas: implications for tumorigenesis.

Authors:  C Parker Gibbs; Valery G Kukekov; John D Reith; Olga Tchigrinova; Oleg N Suslov; Edward W Scott; Steven C Ghivizzani; Tatyana N Ignatova; Dennis A Steindler
Journal:  Neoplasia       Date:  2005-11       Impact factor: 5.715

6.  Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines.

Authors:  Jeongwu Lee; Svetlana Kotliarova; Yuri Kotliarov; Aiguo Li; Qin Su; Nicholas M Donin; Sandra Pastorino; Benjamin W Purow; Neil Christopher; Wei Zhang; John K Park; Howard A Fine
Journal:  Cancer Cell       Date:  2006-05       Impact factor: 31.743

7.  A novel NK-type homeobox gene, ENK (early embryo specific NK), preferentially expressed in embryonic stem cells.

Authors:  Sue-Hong Wang; Ming-Shiun Tsai; Ming-Fu Chiang; Hung Li
Journal:  Gene Expr Patterns       Date:  2003-03       Impact factor: 1.224

8.  An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors.

Authors:  Ittai Ben-Porath; Matthew W Thomson; Vincent J Carey; Ruping Ge; George W Bell; Aviv Regev; Robert A Weinberg
Journal:  Nat Genet       Date:  2008-05       Impact factor: 38.330

9.  CD133, a novel marker for human prostatic epithelial stem cells.

Authors:  Gavin D Richardson; Craig N Robson; Shona H Lang; David E Neal; Norman J Maitland; Anne T Collins
Journal:  J Cell Sci       Date:  2004-06-29       Impact factor: 5.285

10.  Methodologies in assaying prostate cancer stem cells.

Authors:  Hangwen Li; Ming Jiang; Sofia Honorio; Lubna Patrawala; Collene R Jeter; Tammy Calhoun-Davis; Simon W Hayward; Dean G Tang
Journal:  Methods Mol Biol       Date:  2009
View more
  6 in total

1.  Downregulation of the transcription factor, FoxD3, is associated with lymph node metastases in invasive ductal carcinomas of the breast.

Authors:  Hua Zhao; Daozhen Chen; Jiayuan Wang; Yongxiang Yin; Qiong Gao; Ye Zhang
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15

Review 2.  Emerging role of nanog in tumorigenesis and cancer stem cells.

Authors:  Luis E Iv Santaliz-Ruiz; Xiujie Xie; Matthew Old; Theodoros N Teknos; Quintin Pan
Journal:  Int J Cancer       Date:  2014-01-13       Impact factor: 7.396

3.  Immunohistochemical expression of four different stem cell markers in prostate cancer: High expression of NANOG in conjunction with hypoxia-inducible factor-1α expression is involved in prostate epithelial malignancy.

Authors:  Katsuhito Miyazawa; Takuji Tanaka; Dan Nakai; Nobuyo Morita; Koji Suzuki
Journal:  Oncol Lett       Date:  2014-06-23       Impact factor: 2.967

4.  Isolation and enrichment of PC-3 prostate cancer stem-like cells using MACS and serum-free medium.

Authors:  Xia Sheng; Zeng Li; DE-Lin Wang; Wen-Bin Li; Zhao Luo; Ke-Hong Chen; Jian-Jia Cao; Chao Yu; Wu-Jiang Liu
Journal:  Oncol Lett       Date:  2012-12-21       Impact factor: 2.967

5.  A modified method for isolation of bladder cancer stem cells from a MB49 murine cell line.

Authors:  Yong-tong Zhu; Cheng-yong Lei; Yang Luo; Na Liu; Cheng-wu He; Wei Chen; Fei Li; Yong-jian Deng; Wan-long Tan
Journal:  BMC Urol       Date:  2013-11-04       Impact factor: 2.264

6.  Targeting aggressive prostate cancer-associated CD44v6 using phage display selected peptides.

Authors:  Ying Peng; Austin R Prater; Susan L Deutscher
Journal:  Oncotarget       Date:  2017-09-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.